Get started
Author

Mutlu Hızal

Observed names: HIZAL, MUTLU, Hızal, Mutlu, M. Hizal, Mutlu HIZAL, Mutlu Hizal, hızal, mutlu
Observed institutions: Ministry of Health, Sağlık Bilimleri Üniversitesi, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Ankara Yıldırım Beyazıt University, Ankara Bilkent City Hospital, Ankara Etlik City Hospital, Gülhane Eğitim ve Araştırma Hastanesi, Gazi University
ORCID: 0000-0001-5147-4431
Observed ORCID: 0000-0001-5147-4431
OpenAlex ID: A5056164245
The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer
2019 · Hatime Arzu Yasar, Kadriye Bir Yucel, et al. · Journal of Oncology Pharmacy Practice · 28
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
2023 · Seda Kahraman, Enes Erul, et al. · Future Oncology · 27
Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization
2018 · MehmetAli Nahit Sendur, Burak Bilgin, et al. · Journal of Cancer Research and Therapeutics · 22
Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)
2020 · Mutlu Hizal, Mehmet AN Sendur, et al. · Journal of Oncology Pharmacy Practice · 14
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
2022 · Mustafa Gürbüz, Yasin Kutlu, et al. · Journal of Cancer Research and Clinical Oncology · 13
An update on immunotherapy options for urothelial cancer
2019 · Burak Bilgin, Mehmet A. N. Sendur, et al. · Expert Opinion on Biological Therapy · 13
Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?
2015 · Mutlu Hizal, Cosimo Bruni, et al. · Clinical Rheumatology · 12
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
2022 · Emre Yekedüz, Serdar Karakaya, et al. · Clinical Genitourinary Cancer · 9
Evaluation of dynamic serum thiol/disulfide homeostasis in locally advanced and metastatic gastric cancer
2018 · Mutlu Hizal, Mehmet A.N. Sendur, et al. · Journal of Oncological Sciences · 8
Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer
2017 · Burak Bilgin, Mehmet AN Şendur, et al. · Future Oncology · 8
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
2025 · Seda Kahraman, Enes Erul, et al. · Clinical Breast Cancer · 7
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
2022 · Mutlu Hizal, Burak Bilgin, et al. · Journal of Cancer Research and Clinical Oncology · 7
PDF
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
2022 · Cihan Erol, Mehmet Ali Nahit Sendur, et al. · Journal of Cancer Research and Therapeutics · 7
The relationship between adjuvant chemotherapy and thiol-disulfide compounds
2022 · Pınar Akyol, Didem Şener Dede, et al. · Journal of Cancer Research and Therapeutics · 7
Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database
2021 · Emre Yekedüz, İsmail Ertürk, et al. · Future Oncology · 7
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
2021 · Burak Bilgin, Mehmet Ali Nahit Sendur, et al. · Journal of Cancer Research and Clinical Oncology · 7
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
2024 · Seda Kahraman, Mutlu Hizal, et al. · BMC Cancer · 6
PDF
A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint
2020 · Mutlu Hizal, Mehmet A. N. Sendur, et al. · Current Medical Research and Opinion · 5
Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis
2024 · Mutlu Hizal, Abdurrahman Tufan, et al. · Scientific Reports · 4
PDF
Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations
2023 · Seda Kahraman, Murat Bardakci, et al. · Journal of Cancer Research and Therapeutics · 4
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
2021 · Mutlu Hizal, Burak Bilgin, et al. · Journal of Cancer Research and Clinical Oncology · 4
PDF
The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer
2020 · Burak BİLGİN, Mutlu HIZAL, et al. · Tuberkuloz ve Toraks · 4
PDF
Evaluation of dynamic serum thiol-disulphide homeostasis in colorectal cancer
2019 · Burak Bilgin, Mehmet AN. Sendur, et al. · Journal of Oncological Sciences · 4
Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study
2025 · Safa Can Efil, Sema Nur Ozsan Celebi, et al. · International Journal of Cancer · 3
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer
2025 · Furkan Ceylan, Safa Can Efil, et al. · Expert Review of Anticancer Therapy · 3
Works count: 102
Citation count: 258
H-index: 8
I10-index: 7
Year
Topic
Type